Outlook Therapeutics, Inc. (OTLK)
| Market Cap | 109.55M +97.4% |
| Revenue (ttm) | -1.16M |
| Net Income | -61.12M |
| EPS | -0.75 |
| Shares Out | 243.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,255,559 |
| Open | 0.4364 |
| Previous Close | 0.4364 |
| Day's Range | 0.4350 - 0.4661 |
| 52-Week Range | 0.1611 - 2.5380 |
| Beta | 0.72 |
| Analysts | Buy |
| Price Target | 5.03 (+1,016.67%) |
| Est. Earnings | Dec 18, 2026 |
About OTLK
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for OTLK stock is "Buy." The 12-month stock price target is $5.03, which is an increase of 1,016.67% from the latest price.
News
Outlook Therapeutics announces Greg DiPasquale as chief commercial officer
Outlook Therapeutics (OTLK) announced Greg DiPasquale as chief commercial officer. DiPasquale, who joined Outlook in December 2025 as head of commercial for Lytenava, will lead all commercial function...
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
Veteran retina commercial leader, who has helped launch BEOVU®, EYLEA® and EYLEA® HD, to lead U.S. commercialization of LYTENAVA™ (bevacizumab-vikg) Veteran retina commercial leader, who has helped la...
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor Discussion
Segment features Kevin Lundquist discussing his decision to join Outlook Therapeutics and the Company's path forward following the FDA approval of LYTENAVA™
Outlook submits HCPCS Level II application to CMS for J-code for LYTENAVA
Outlook Therapeutics (OTLK) announced that it has submitted an application to the Centers for Medicare & Medicaid Services, CMS, requesting a permanent, product-specific Healthcare Common Procedure Co...
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
Application represents an important step in supporting reimbursement Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026 ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -...
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Ionis Pharmaceuticals, Inc. today announced positive...
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst
Outlook Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
FDA approval of LYTENAVA marks the first FDA-approved ophthalmic bevacizumab for wet AMD, offering regulated supply and support. The U.S. launch targets early adopters dissatisfied with repackaged products, with a sub-$500 price. Success will be measured by coverage, conversion, and reorder rates, with scaling after the permanent J-code in April 2027.
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
Access the segment here
Outlook CFO Lawrence Kenyon to step down, Kevin Lundquist to succeed
Outlook Therapeutics (OTLK) announced the appointment of Kevin Lundquist as CFO, effective September 1. Lundquist most recently served as CFO of CapsoVision (CV). In connection with Lundquist’s appoin...
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industries Deep expertise span...
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
Video webcast now available here
Outlook Therapeutics announces common stock, warrants offering
Outlook Therapeutics (OTLK) announced that it has commenced an underwritten public offering of its common stock and accompanying warrants to purchase shares of its common stock. All of the securities…
Outlook Therapeutics $100M Spot Secondary re-offered at 99c
Piper Sandler and BTIG are acting as joint book running managers for the offering.
Outlook Therapeutics 55.6M share Spot Secondary priced at 99c
Piper Sandler and BTIG acted as joint book running managers for the offering.
Outlook Therapeutics reports Q3 EPS (15c), consensus (8c)
Reports Q3 revenue $9,000, consensus $966,670. “FDA approval of LYTENAVA marks a defining moment for Outlook Therapeutics (OTLK) and creates a significant opportunity for the Company in the United Sta...
Outlook Therapeutics Earnings Call Transcript: Q3 2026
FDA approval of LYTENAVA positions it as the only approved ophthalmic bevacizumab for wet AMD in the U.S., targeting a $8.5B retina market. First-year U.S. launch revenue is guided at $50–75M, with peak U.S. sales potential of $500M by 2030, supported by a $55M capital raise.
Outlook Therapeutics Earnings release: Q3 2026
Outlook Therapeutics released its Q3 2026 earnings on August 14, 2026, summarizing the period's financial results.
Outlook Therapeutics Quarterly report: Q3 2026
Outlook Therapeutics has published its Q3 2026 quarterly earnings report on August 14, 2026.
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
The only FDA-approved ophthalmic bevacizumab, LYTENAVA TM , addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTE...
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTE...
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
ISELIN, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, ...
Outlook Therapeutics price target raised to $1.60 from 50c at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Outlook Therapeutics (OTLK) to $1.60 from 50c and keeps a Neutral rating on the shares after the FDA approved…
Outlook Therapeutics upgraded to Buy from Neutral at BTIG
BTIG upgraded Outlook Therapeutics (OTLK) to Buy from Neutral with a $4 price target following FDA approval of LYTENAVA for wet AMD. Outlook Therapeutics has shifted from regulatory uncertainty to…